An 8-year-old intact female Cavalier King Charles Spaniel...

Thank you for reaching out about this interesting case. An 8-year-old intact female Cavalier King Charles Spaniel with a newly detected Grade III/VI left apical systolic murmur, mild cardiomegaly (VHS 11.2), and mildly elevated ProBNP requires a careful, methodical approach to staging and management.

Let's break this down according to the ACVIM Consensus Guidelines for Myxomatous Mitral Valve Disease (DMVD).

Staging of Your Patient

Based on the information provided, this patient would be classified as ACVIM Stage B2 DMVD.

Here is my reasoning:

Presence of Structural Heart Disease: The Grade III/VI left apical systolic murmur is highly consistent with mitral regurgitation due to DMVD, which is the most common acquired heart disease in dogs, particularly in Cavaliers. The point of maximal intensity (PMI) at the left apex and systolic timing are classic for mitral valve regurgitation.

Asymptomatic Status: The patient is described as asymptomatic, meaning she has no current or historical clinical signs of congestive heart failure (CHF) such as coughing, tachypnea, dyspnea, or syncope. This immediately rules out Stage C or D heart failure.

Evidence of Hemodynamically Significant Remodeling: This is the critical factor that differentiates Stage B1 from Stage B2.

Radiographic Cardiomegaly: A Vertebral Heart Score (VHS) of 11.2 suggests cardiomegaly. While Cavaliers can have slightly higher normal VHS values than other breeds, 11.2 is above the widely accepted general dog upper limit of 10.7. More importantly, the presence of any* documented cardiomegaly on radiographs (beyond normal breed variation) indicates that hemodynamically significant remodeling has occurred.
* Elevated ProBNP: While not a definitive staging tool on its own, a mildly elevated ProBNP supports the presence of myocardial stretch and stress, which is consistent with early remodeling secondary to volume overload from mitral regurgitation. It acts as a biomarker that aligns with the radiographic findings.

Therefore, the combination of structural heart disease (murmur) and evidence of cardiac remodeling (cardiomegaly on radiographs) in an asymptomatic patient definitively places her in Stage B2.

When Referral to a Veterinary Cardiologist is Indicated

Referral to a board-certified veterinary cardiologist is strongly indicated now for this Stage B2 patient.

Here's why:

Confirmation and Quantification of Stage B2: While the radiographs suggest cardiomegaly, a comprehensive echocardiogram is essential to precisely quantify the degree of left atrial and left ventricular enlargement (e.g., LA:Ao ratio, LVIDdN, LA volume assessment). This will confirm the B2 diagnosis, assess the severity of mitral regurgitation, and help predict the risk of progression to CHF.

Initiation of Evidence-Based Therapy: The EPIC trial demonstrated a significant survival benefit and delayed onset of CHF in Stage B2 DMVD dogs treated with pimobendan. However, accurate staging via echocardiography is paramount before initiating this therapy. Starting pimobendan in a Stage B1 patient (no significant remodeling) is not supported by evidence and can be detrimental.

Baseline for Monitoring and Prognosis: A detailed echocardiogram provides crucial baseline measurements against which future progression can be monitored. It also allows for a more accurate assessment of prognosis.

Exclusion of Concurrent Diseases: While less likely given the breed and murmur characteristics, an echo can rule out other cardiac conditions that might present with a murmur and cardiomegaly.

Initial Recommendations for the General Practitioner

Before referral, I would advise you to:

* Educate the Owner on Sleeping Respiratory Rate (SRR): This is the single most useful home monitoring tool. Instruct the owner to count their dog's breaths per minute while she is sleeping soundly. A normal SRR is typically less than 30 breaths per minute. Any sustained increase (e.g., >35-40 bpm) could be an early indicator of impending CHF and warrants immediate re-evaluation.
Avoid Diuretics: Do not* initiate furosemide at this stage. Furosemide is indicated for active CHF (Stage C/D) to relieve pulmonary edema or pleural effusion. In a Stage B2 patient, it offers no benefit and can cause dehydration, azotemia, and activate the renin-angiotensin-aldosterone system (RAAS), which can be counterproductive.
Avoid Pimobendan (for now): While pimobendan is the cornerstone of Stage B2 therapy, it should only be initiated after* echocardiographic confirmation of hemodynamically significant remodeling by a cardiologist.

In summary, your patient is at a critical juncture where specialist intervention can significantly impact her quality and duration of life. The accurate staging and timely initiation of appropriate therapy, guided by echocardiography, are paramount.